Wells Fargo & Company Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price objective hoisted by investment analysts at Wells Fargo & Company from $423.00 to $466.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective indicates a potential downside of 6.84% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Wednesday. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $513.80.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $34.87 during trading hours on Thursday, hitting $500.23. 156,025 shares of the company’s stock traded hands, compared to its average volume of 341,693. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $537.19. The firm has a market capitalization of $21.54 billion, a P/E ratio of 18.96, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85. The business has a fifty day moving average price of $484.71 and a 200-day moving average price of $444.09.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the business posted $6.19 earnings per share. As a group, equities analysts predict that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total transaction of $520,000.00. Following the completion of the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,178,800. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $476.34, for a total transaction of $3,953,622.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,520,261.54. The trade was a 18.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 411,954 shares of company stock worth $199,552,088 over the last quarter. Insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Torren Management LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth about $31,000. Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $48,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Management is targeting a roughly $4 billion revenue run rate by 2027 as several late‑stage/new product launches approach, providing a clear growth thesis that investors rewarded. Seeking Alpha article
• Positive Sentiment: Q4 beat on EPS: United Therapeutics reported $7.70 EPS vs. consensus $6.78 and delivered record full‑year revenue of $3.18B (11% YoY), supporting the rally despite the revenue miss versus the quarter’s sales estimate. BusinessWire press release
• Positive Sentiment: Options flow was bullish into the print: unusually large call buying suggests traders were positioning for further upside or volatility after the report (elevates short‑term upside momentum).
• Neutral Sentiment: Analysts remain mixed/neutral into the print — several firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution on near‑term headwinds despite pipeline upside. TipRanks: BTIG Hold rationale
• Neutral Sentiment: Street note/analysis summaries (Zacks) highlight the EPS beat but show some mixed metric performance vs. estimates — useful for modeling revisions but not a clear buy/sell signal by itself. Zacks analysis
• Negative Sentiment: Revenue missed the quarter’s sales consensus ($790.2M actual vs. ~$814.8M expected), which prompted an earlier pullback and is a reminder that top‑line execution still matters to the multiple. Investing.com coverage
• Negative Sentiment: Significant insider selling — the COO and a director disclosed multi‑lot sales in February (COO sale ~14,440 shares plus other recent disposals), which can create investor concern about near‑term insider conviction. InsiderTrades report

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.